Buradasınız

Anasayfa » Content

Derleme: Yaygın Geli şimsel Bozukluklarda Güncel Antipsikotik Kullanımı

Review: Current Antipsychotic Use In Pervasive Developmental Disorders

Journal Name:

  • Maltepe Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objective: Pervasive Developmental Disorders (PDD) are chronic and neurobiological-basis disorders that are childhood-onset. Generally, behavioural and educational interventions are starting points of the treatment. Phar-macological interventions are used to eliminate difficulties which are associated with the disorder, and thus to in-crease functionality as well as to facilitate the administra-tion of other interventions more effectively. Antipsychotic medications are frequently used in the treatment of PDD symptoms like aggressive behaviours, tantrums, irritability, self-injury, impulsivity, speech-delay, social withdrawal and mood changes. In this article, studies of children with PDD who received antipsychotic treatment are reviewed and it is aimed to discuss tolerability end efficacy of the agents.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Yaygın Gelişimsel Bozukluklar (YGB), çocukluk çağı başlangıçlı, kronik ve nörobiyolojik temelli bozukluk¬lardır. Genellikle tedaviye başlangıç noktası, davranışçı ve eğitsel müdahalelerdir. Farmakolojik müdahaleler, bo¬zukluğa eşlik eden güçlüklerin ortadan kaldırılarak gerek işlevselliğin arttırılmasında gerekse bu sayede diğer mü¬dahalelerin daha etkin bir şekilde uygulanmasında kul¬lanılmaktadırlar. Antipsikotik ilaçlar, YGB'de görülen sal¬dırganlık, kendine zarar verici davranışlar, öfke nöbetleri, iritabilite, dürtüsellik, konuşma gecikmesi, sosyal çekilme ve duygudurum değişiklikleri semptomlarının tedavisinde sıklıkla kullanılmaktadırlar. Bu yazıda YGB'li çocuklarla antipsikotik kullanılarak yapılmış araştırılmalar gözden geçirilerek, kullanılan ajanların tolere edilebilirlik ve etkin¬liklerinin tartışılması amaçlanmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-derleme-yaygin-geli-simsel-bozukluklarda-guncel-antipsikotik-kullanimi.pdf
  • 1
42
48
  • Turkish

REFERENCES

References: 

KAYNAKLAR
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev.Washington, DC:APA, 2000:66-78.
2. Klin A, Volkmar FR. Asperger syndrome: diagnosis and external validity. Child Adolesc Psychiatr Clin N Am. 2003;12:1-13.
3. Volkmar F, Cook EH Jr, Pomeroy J, et al. Practi-ce parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry
I999;38 suppl I2:32-54.
4. Scahill L, Koenig K, Carroll DH, et al. Risperidone approved for the treatment of serious behavioral prob-lems in children with autism. J Child Adolesc Psychiatr
Nurs. 2007;20:I88-I90.
5. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs.
2007;9:343-354.
6. Soorya L, Kiarashi J, Hollander E. Psychopharma-cologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am.
2008;I7:753-77I.
7. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;I7:787-
80I
8. Nickels K, Katusic SK, Colligan RC, et al. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Dev Behav
Pediatr. 2008;29:75-8I.
9. Mandell DS, Morales KH, Marcus SC, et al. Psy-chotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics.
2008;I2I:44I-448.
10. Leskovec TJ, Rowles BM, Findling RL. Pharmaco-
logical treatment options for autism spectrum disor-
ders in children and adolescents. Harv Rev Psychiatry.
2008;I6:97-II2.
11. Dover CJ, Le Couteur A. How to diagnose autism.
Arch Dis Child. 2007;92:540-545.
12. Chavez B, Chavez-Brown M, Sopko MA Jr, et al. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs. 2007;9:249-
266.
13. Miral S, Gencer O, Inal-Emiroglu FN, et al. Rispe-ridone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.
Eur Child Adolesc Psychiatry. 2008;I7:I-8.
14. Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr
Clin N Am. 2008 ;I7:7I3-738.
15. McCracken JT, McGough J, Shah B, et al; Rese¬arch Units on Pediatric Psychopharmacology Autism Network.Risperidone in children with autism and se-rious behavioral problems. University of N Engl J Med.
2002;347:3I4-32I..
16. McDougle CJ, Scahill L, Aman MG. Risperido-ne for thecore symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.Am J Psychiatry 2005;162:1142-1148.
17. Chavez B, Chavez-Brown M, ReyJA.Role of ris-peridone in children with autism spectrum disorder.
Ann Pharmacother. 2006;40:909-9I6.
18. Parikh MS, Kolevzon A, Hollander E. Psychop¬harmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol. 2008;18:157-178.
19. NewcomerJW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence J Clin Psychiatry. 2007;68 Suppl I:20-27.
20. Anderson LT, Campbell M, learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19:227-239.
21. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad
Child Adolesc Psychiatry. I989;28:87-92.
22. Malone RP, Gratz SS, Delaney MA, et al. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders.
CNS Drugs 2005;I9:923-934.
23. Cohen IL, Campbell M, Posner D. Behavioral

effects of haloperidol in young autistic children. J Am
Acad Child Adolesc Psychiatry I980;I9: 665-677.
24. Anderson LT, Campbell M, Grega DM. Halope-ridol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry
1984; 141:1195-1202.
25. Campbell, M.. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am.
Acad. Child Adolesc. Psychiatry. I997;36:835-843.
26. Gencer O, Emiroglu FN, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child
Adolesc Psychiatry. 2008;I7:2I7-225.
27. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry.
200I;40:887-894.
28. Naruse H, Nagahata M, Nakana Y. A multicenter double-blind trial of pimozide, haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr I982;48:I73-I84.
29. Ernst M, Magee HJ, Gonzalez NM, et al. Pi-
mozide in autistic children. Psychopharmacol Bull 1992;28:187-191.
30. Pandina GJ, Bossie CA, Youssef E, et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37:367-373.
31. McDougle CJ, Scahill L, McCracken JT. Research Units on Pediatric Psychopharmacology (RUPP) autism network. Background and rationale for an initial con-trolled study of risperidone. J Am Acad Child Adolesc
Psychiatry 2000; 9: 20I-224.
32. Canitano R, Scandurra V. Risperidone in the tre¬atment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat.
2008;4:723-730.
33. Shea S, Turgay A, Carroll A. Risperidone in the treatment of disruptive behavioral symptoms in child-ren with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:634-641.
34. Malone RP. Discontinuing risperidone results in relapse in children with autism spectrum disorders.
Evid Based Ment Health. 2006;9:56.
35. Troost PW, Lahuis BE, Steenhuis MP. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137-1144.
36. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism randomized, placebo controlled, double-
blind study. J. Child Neurol. 2006; 2I:450-455.
37. LubyJ, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc
Psychopharmacol. 2006;I6:575-587.
38. Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry. 2004;161:918-920.
39. Kumra S, Herion D, Jacobsen LK, et al. Case study: risperidone-induced hepatotoxicity in pediatric patients. J
Am Acad Child Adolesc Psychiatry. I997;36:70I-705.
40. Erdogan A, Atasoy N, Akkurt H, et al. Risperidone and liver function tests in children and adolescents: a short-term prospective study. Prog Neuropsychophar-
macol Biol Psychiatry. 2008;32:849-857.
41. Hergüner S, Mukaddes NM. Risperidone-Induced Enuresis in Two Children with Autistic Disorder.. J Child Adolesc Psychopharmacol. 2008; No:I3.
42. Potenza MN, Holmes JP, Kanes SJ, et al. Olan-zapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
43. Stavraki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. Journal of Psychiatry and Neu-
roscience 2004;29:57-60.
44. Kemner, C., Willemsen-Swinkels, S.H., de Jonge, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J. Clin. Psychophar-
macol. 2002;22:455-460.
45. Hollander E, Wasserman S, Swanson EN. A doub-leblind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006:16:541-548.
46. Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 15: 37-38.

47. Gogtay N, RapoportJ. Clozapine use in children and rasidone in adolescents with autism: an open-label pilot adolescents. Expert Opin Pharmacother. 2008;9:459- study. J Child Adolesc Psychopharmacol. 2007;I7:779-
465. Review. 790.

48. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:99-107.
49. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;I4:287-294.
50. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry.
2004;65:I53I-I536.
51. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord.
2005;35:387-39I.
52. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in yout-hs with autism. J Am Acad Child Adolesc Psychiatry.
2002;4I:92I-927.
53. Cohen, S.A., Fitzgerald, B.J., Khan, S.R., et al. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J. Clin.Psychiatry. 2004; 65:110-113.
54. Malone RP, Delaney MA, Hyman SB, et al. Zip-
55. Duggal HS. Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol.
2007;I7:26I-263.
56. Goforth HW, Rao MS.Improvement in behaviour and attention in an autistic patient treated with zipra-
sidone. Aust N Z J Psychiatry. 2003;37:775-776.
57. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
Psychopharmacol Bull. 200I;35:66-79.
58. Stigler KA, Posey DJ, McDougle CJ Aripiprazole for maladaptive behavior in pervasive developmental disorders.. J Child Adolesc Psychopharmacol. 2004;I4:455-
463.
59. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol. 2006;16:549-560.

60. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol.
2005;20:603-6I0.
61. Shastri M, Alla L, Sabaratnam M.Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. J Psychopharmacol.
2006;20:863-867.

Thank you for copying data from http://www.arastirmax.com